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Materials and methods. We evaluated all the patients treated in our department after breast reconstruction with expanders. All of
them started the treatment after the last expansion and all were treated with full expander. Aesthetic evaluation was performed
by the Aesthetic and Plastic Surgery Department. If necessary, patients received local massages for early intervention on ﬁbrosis.
All of them received 50Gy/25 fractions. We studied dosimetric disturbances produced by the expander membrane.
Results. We evaluated 33 patients. We did not observe any difference in acute toxicity compared to conventional treatment or
dosimetric disturbances >5%. None of the patients suffered from infection, dehiscence or necrosis, but all of them experienced
a different grade of ﬁbrosis. This was minimized with the prescription of local massages performed by the Aesthetic and Plastic
Surgery Department. Aesthetic outcome was ﬁnally good or excellent in 90% evaluated by physician and patient.
Conclusion. If we have to treat a reconstructed patient, there is no reason why we should avoid performing it with a full expander,
but all the management should be monitored in a multidisciplinary team.
http://dx.doi.org/10.1016/j.rpor.2013.03.721
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Introduction. Hypofractionated radiation consists on fewer, larger-dose radiation treatments administered in shorter periods than
the standard treatment does. Randomized trials of hypofractionated whole breast irradiation have demonstrated compara-
ble outcomes as conventional fractionation. Doses to organs at risk should be minimized while coverage of the breast is not
compromised.
Purpose. To determine the impact of the different schedules of hypofractionated radiation therapy in breast cancer over organs at
risk and to compare the results with GICOR’s recommendations (Spanish Group of Clinical Investigation in Radiation Oncology)
Methods. Retrospective analyses of dose–volume histogram parameters in organs at risk (lungs, heart, spine and contralateral
breast) in 100 patients treated with hypofractionated external radiation therapy from September 2011 to December 2012 after
breast-conserving surgery. Five groups were formed: (a) breast irradiation without boost, (b) breast irradiation with a boost of
8.01Gy, (c) breast irradiation with a boost of 10.68Gy, (d) breast irradiation with a boost of 13.35Gy and (e) breast irradiation with
supraclavicular area with or without boost. The dose to the whole breast was 40.05Gy.
Results. Median age: 58.7 years. Tumor stage: unknown (Tx or Nx) 3%, 0 (CDIS) 2%, I 65%, II 28%, III 2%. Patient distribution among
groups: group A 26 patients, group B 18 patients, group C 3 patients, group D 49 patients and group E 4 patients. Median breast
volume: 654.7 cm3 (range 260.8–1553.8 cm3). Breast coverage by the prescription dose: 97.5% (range 84.9–100%). Organs at risk:
median ipsilateral lung V30: 101.7 cm3 (range 7.7–253.4 cm3), V20<=25% for both lungs was fulﬁlled in all cases. Median heart
V30 was 2.3 cm3 (range 0–38.1 cm3).
Conclusion. Our series matches GICOR’s recommendations. We recommend the routinely evaluation with dose volume histogram
for all the organs at risk mentioned above in hypofractionated breast irradiation after breast-conserving surgery.
http://dx.doi.org/10.1016/j.rpor.2013.03.722
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Purpose. To evaluate for the ﬁrst time the role of radical radiotherapy at high doses given by hyperfractionated schemes as unique
locoregional treatment as an encouraging alternative to prevent mastectomies in such unresponsive to systemic therapy Stage
IIIB patients.
Patients and methods. 184 women were referred from 1991 to 2010 to hyperfractionated radiotherapy. Mean age 59 years. All but
2 patients (T3) were staged as T4 (84 cases (T4d)) and 88 (47.8%) were classiﬁed as N0. Whole breast was treated to a dose of
60Gy on 1.2Gy/bid, followed by a boost with escalating prescribed doses from 9.6Gy (12 cases), 12Gy (18 cases) and 21.6Gy (154
cases) achieving a total dose of 69.6, 72 and 81.6Gy respectively. Peripheral node areas were treated by conventional fractionation.
Tumor volume mean dose was 79.4±4.7 median 81.6 range 57.6–86.4. Treatment was delivered in 51±8 days, median 50.
Results. Mean follow-up for survivors was 109.44±70.04 months, median 106, range 6–248 months among surviving patients.
Local disease free survival at 5, 10, 15 years was 85.2%, 81.5%, and 81.5%. Cause speciﬁc survival at 5, 10 and 15 years was 60.2%,
50.2% and 37.1%, respectively with a median survival 85±18.96 months (CI 95% 47.83–122.16 months). Radiation dose was the
only prognostic factor for local control (p<0.0001). Toxicity was evaluated by the RTOG scale. Severe acute toxicity (RTOG Grades
3) was present in 32 (17.3%) cases. Severe late cutaneous and subcutaneous toxicity was present in 18% and 30% of the cases,
respectively. DSB analysis and microarrays studies were evaluated in some patients.
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Conclusions. Hyperfractionated radiotherapy achieves high loco-regional control rates, irrespective of reduced survival caused by
metastatic progression. After a long follow-up period of our study, late toxicity observed in cases treated in early times were
related to biological characteristics of intrinsic radiosensitivity as initial damage DSB and constitutive gene pathways.
http://dx.doi.org/10.1016/j.rpor.2013.03.723
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Introduction. Breast-conserving surgery followed by whole breast irradiation is a standard treatment of early breast cancer. The
application of postoperative radiotherapy reduces by two-thirds the risk of 10-years local recurrence and increase the rate of
10-years survival by 5%. There are radiobiological reasons justifying the use of hypofractionation in breast cancer. Since the ˛/ˇ
value of breast cancer has been estimated around 4Gy, high fraction doses may be more efﬁcient. However, these doses may also
increase the frequency and severity of side effects in normal tissues.
Objectives. According to the results published of four phase III trials that compared standard treatment versus hypofractionated
treatments, since 2008 we started in our centers, a hypofractionation protocol in patients with early breast cancer. The purpose
of the study is to communicate the preliminary results.
Materials and methods. 578 patients with breast cancer were treated between 2008 and 2011 by hypofractionation regimen and an
additional hypofractionated boost to the tumor bed in those patients at high risk of local recurrence.
Results. With a maximum follow up of 52 months, the median age of the patients was: 57 years (25–87). Tumor size (TNM): In situ:
10% (56 patients), T1: 69%, T2: 20%, T3: 1% surgery of the axila was lymphadenectomy in 25% and sentinel node biopsy in 70%;
positive axillary nodes were found in 15%. The median prescribed dose to the whole breast was 42.56Gy, with a fractionation
of 2.66Gy. Median additional boost administered was 7.98Gy. Acute skin reactions (toxicity criteria RTOG): G0: 28%, G1: 56%, G2:
10%, G3: 2%, there was no G4 toxicity. There were no acute adverse cosmetic results (assessed in agreement with the Harvard
criteria).
Conclusions. The explored hypofractionated radiotherapeutic approach for early breast cancer seems to be feasible providing
consistent clinical results with excellent short-to-medium-term toxicity proﬁle.
http://dx.doi.org/10.1016/j.rpor.2013.03.724
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Introduction. The scheme of standard radiotherapy for breast cancer treatment involves a high total dose in 25 fractions. However,
a decrease in the total dose, together with an increase in the dose per fraction (hypofractionation) is discussed to be at least as
effective as standard treatment.
Objective. To analyze the results in local control, acute and late toxicity and cosmetic outcome in patients treated with hypofrac-
tionated radiation therapy after conservative surgery for breast cancer in our center.
Materials and methods. A retrospective analysis of all women diagnosed with breast cancer and treated with breast-conserving
surgery followed by hypofractionated scheme from 2006 to 2011. Total dose on mammary gland: 42.4–2.65Gy/fraction, for a total
of 16 sessions with concomitant boost to 7.7Gy (0.48Gy/fraction). We included patients treated with chemotherapy, hormonal
therapy and trastuzumab.
Results. We have treated 143 women with hypofractionated scheme. After a median follow up of 30 months, the local recurrence
rate was 0%, only 2.2% experienced nodal relapse, one patient developed a contralateral breast cancer and 7.4% had distant
metastases. There was no acute toxicity in 28.4% of cases, being the most frequent grade 1 radiodermatitis (61.1%). Regarding
late toxicity, this was not observed in 65.6%, being grade 1 ﬁbrosis in the treated area the most common. The aesthetic result
was good or excellent in 90% of patients treated. At the end of the study, 88.1% remained alive without disease, 5.2% alive with
disease, 3% exitus due to tumor and 3.7% were died due to other causes.
Conclusion. The hypofractionated scheme after conservative surgery in breast cancer provides a good control of the disease
without causing excessive toxicity and providing good aesthetic results. Similar results to standard treatment can be obtained
with a signiﬁcant reduction in overall treatment time.
http://dx.doi.org/10.1016/j.rpor.2013.03.725
